Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO 2024)
San Diego, California, US 16 March 2024 - 19 March 2024
Olanzapine vs fosaprepitant: Which is better for CINV prevention?
Olanzapine appears to be just as effective as fosaprepitant, a neurokinin-1 receptor antagonist (NK1-RA), in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic malignancies who were receiving carboplatin/paclitaxel chemotherapy every 3 weeks, a prospective study presented at SGO 2024 suggests. However, the former trumps the latter in terms of cost effectiveness.
MIRASOL PRO data boost mirvetuximab soravtansine potential in FRα-positive ovarian cancer
Patient-reported outcomes (PROs) from the phase III MIRASOL trial underpin the potential of the antibody drug conjugate mirvetuximab soravtansine (MIRV) to improve health-related quality of life (HRQoL) in women with folate receptor-alpha positive platinum-resistant ovarian cancer (FRα-positive PROC) as opposed to investigator’s choice of chemotherapy.
Dostarlimab-chemo a new SoC for endometrial cancer?
In the second interim analysis of part 1 of the phase III ENGOT-EN6-NSGO/GOG-3031/RUBY trial, dostarlimab plus carboplatin/paclitaxel (CP) chemotherapy delivered a significant survival benefit in women with primary advanced or recurrent endometrial cancer.
Apixaban cheaper, on par with enoxaparin as VTE prophylaxis in gynaecologic cancer patients
Patients with gynaecologic cancer who used apixaban for postoperative venous thromboembolism (VTE) prophylaxis achieve similar 90-day and lower 30-day rates of VTE when compared with those who used enoxaparin, reports a study presented at SGO 2024.
Maintenance fuzuloparib prolongs survival in ovarian cancer
Maintenance therapy with fuzuloparib results in significant improvements in progression-free survival (PFS) in patients newly diagnosed with advanced ovarian cancer, who showed response to first-line platinum-based chemotherapy (PBC), reports a study (FZOCUS-1) presented at SGO 2024.
